Clough Capital Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-58,100
| Closed | -$1.68M | – | 155 |
|
|
2024
Q3 | $1.68M | Buy |
+58,100
| New | +$1.69M | 0.17% | 72 |
|
|
2023
Q3 | – | Sell |
-68,070
| Closed | -$2.5M | – | 233 |
|
|
2023
Q2 | $2.5M | Sell |
68,070
-84,420
| -55% | -$3.29M | 0.25% | 104 |
|
|
2023
Q1 | $6.22M | Buy |
152,490
+132,890
| +678% | +$5.74M | 0.67% | 50 |
|
|
2022
Q4 | $1M | Buy |
+19,600
| New | +$940K | 0.1% | 129 |
|
|
2022
Q3 | – | Sell |
-330,540
| Closed | -$17.3M | – | 98 |
|
|
2022
Q2 | $17.3M | Sell |
330,540
-136,460
| -29% | -$6.95M | 2.15% | 22 |
|
|
2022
Q1 | $24.2M | Buy |
467,000
+362,910
| +349% | +$18.8M | 1.83% | 18 |
|
|
2021
Q4 | $6.15M | Sell |
104,090
-303,900
| -74% | -$15.1M | 0.41% | 60 |
|
|
2021
Q3 | $17.5M | Sell |
407,990
-406,710
| -50% | -$18M | 1.06% | 38 |
|
|
2021
Q2 | $31.9M | Buy |
814,700
+76,300
| +10% | +$2.97M | 1.73% | 14 |
|
|
2021
Q1 | $26.8M | Buy |
+738,400
| New | +$26.2M | 1.19% | 27 |
|
|
2019
Q2 | – | Sell |
-187,296
| Closed | -$7.55M | – | 132 |
|
|
2019
Q1 | $7.55M | Sell |
187,296
-34,782
| -16% | -$1.39M | 0.66% | 55 |
|
|
2018
Q4 | $9.2M | Hold |
222,078
| – | – | 1.08% | 30 |
|
|
2018
Q3 | $9.29M | Hold |
222,078
| – | – | 0.88% | 39 |
|
|
2018
Q2 | $7.64M | Hold |
222,078
| – | – | 0.68% | 49 |
|
|
2018
Q1 | $7.48M | Hold |
222,078
| – | – | 0.72% | 52 |
|
|
2017
Q4 | $7.63M | Sell |
222,078
-159,154
| -42% | -$5.43M | 0.64% | 52 |
|
|
2017
Q3 | $12.9M | Hold |
381,232
| – | – | 0.87% | 38 |
|
|
2017
Q2 | $12.2M | Hold |
381,232
| – | – | 0.84% | 40 |
|
|
2017
Q1 | $12.4M | Buy |
381,232
+70,934
| +23% | +$2.24M | 0.79% | 39 |
|
|
2016
Q4 | $9.56M | Buy |
310,298
+293,012
| +1,695% | +$8.95M | 0.63% | 53 |
|
|
2016
Q3 | $555K | Hold |
17,286
| – | – | 0.03% | 150 |
|
|
2016
Q2 | $577K | Buy |
+17,286
| New | +$552K | 0.03% | 153 |
|
|
2015
Q1 | – | Sell |
-565,471
| Closed | -$16.7M | – | 225 |
|
|
2014
Q4 | $16.7M | Sell |
565,471
-378,491
| -40% | -$10.9M | 0.6% | 64 |
|
|
2014
Q3 | $26.5M | Buy |
+943,962
| New | +$26.5M | 0.99% | 36 |
|
|
2014
Q2 | – | Sell |
-130,801
| Closed | -$3.99M | – | 216 |
|
|
2014
Q1 | $3.99M | Sell |
130,801
-1,217,265
| -90% | -$36.3M | 0.12% | 140 |
|
|
2013
Q4 | $39.2M | Buy |
1,348,066
+1,054
| +0.1% | +$30.7K | 1.29% | 14 |
|
|
2013
Q3 | $36.7M | Buy |
1,347,012
+34,044
| +3% | +$926K | 1.14% | 17 |
|
|
2013
Q2 | $34.9M | Buy |
+1,312,968
| New | +$36.3M | 1.16% | 20 |
|
Other funds holding PFE
Clough Capital Partners's PFE Position: Q4 2024 in Review
Clough Capital Partners sold out of Pfizer (PFE) in Q4 2024, closing a stake of 58,100 shares — an estimated $1.68M sold.
Clough Capital Partners first reported a position in PFE in Q2 2013 and held it in 28 quarters. The position peaked at $39.2M in Q4 2013. 2,996 funds tracked by Wall St. Rank hold PFE as of Q4 2024.
- Clough Capital Partners reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
- Clough Capital Partners sold 58,100 Pfizer shares in Q4 2024, an estimated $1.68M.
- Clough Capital Partners first reported a position in Pfizer in Q2 2013 and held it in 28 quarters.
- Clough Capital Partners's Pfizer position peaked at $39.2M in Q4 2013.
- 2,996 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.
Based on Clough Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.